| |
TO ALL - New Advisory Board
(Full text of press release from Canadian Corporate News)
AUGUST 28, 1997
Dimethaid Research Establishes Scientific Advisory Board
Appoints Two Prominent Scientists
MARKHAM, ONTARIO--Rebecca Keeler, President and CEO of
Dimethaid Research Inc. (TSE - DMX) announced today that the
Company has created a Scientific Advisory Board. The first
two appointments to the Board are Dr. Angela Mailis of Toronto
and Dr. Gary J. Bennett of Philadelphia.
Dr. Angela Mailis is currently the Director of the
Comprehensive Pain Program and Division Head of Physical
Medicine & Rehabilitation at The Toronto Hospital. She is
also an Associate Professor at the Department of Medicine at
the University of Toronto and Playfair Neuroscience Unit
Associate at The Toronto Hospital and University of Toronto.
She was Director of the Pain Investigation Unit at The
Toronto Hospital for 15 years up until it expanded recently to
become the Comprehensive Pain Program. Dr. Mailis has
published in many scientific journals. Her current research
focus is on human neuropathic pain, description of human pain
syndromes, pain demographics and drug trials for pain. She
received her Medical Degree from, and was a Gold Medalist at,
the University of Athens Medical School, and her Master of
Science Degree from the University of Toronto. She is a
specialist in Physical Medicine and Rehabilitation and has
devoted her carrier exclusively to the diagnosis and treatment
of pain.
Dr. Gary J. Bennett is the Director of Pain Research,
Allegheny Health Education Research Foundation Chronic Pain
Clinic, and Director of the Quantitative Sensory Testing and
Autonomic Nervous System Testing Laboratories, Department of
Neurology, Allegheny University of the Health Sciences in
Philadelphia, PA. Dr. Bennett was awarded the Frederick W.L.
Kerr Basic Science Research Award by the American Pain Society
in 1996, has been associate editor of PAIN, the journal of the
International Association on the Study of Pain since 1986 and
the co-editor-in-chief of The Pain Medicine Journal Club
Journal since 1994. He received his Ph.D. from Virginia
Commonwealth University, and is one of the world's best known
basic scientists in the field of pain research.
"We are honoured to have such esteemed scientists
contribute to the development of our platform transdermal drug
delivery system," Mrs. Keeler stated. "As we move closer to
the commercialization of PENNSAID(tm), our arthritis pain
relief medication, we want to not only explore new indications
for this drug, but also the use of our drug delivery system
for other pain medications. The combined expertise from these
two individuals in the area of pain will be an invaluable
asset to us as we move forward - we will value their
contributions greatly," Mrs. Keeler added.
Dimethaid Research Inc. is a pharmaceutical company
engaged in the development and commercialization of innovative
therapeutic products which work with the body's own healing
mechanisms. The Company's major products under clinical
development are PENNSAID(tm), a topical arthritis pain relief
medication, and an immune modulator called WF10, owned by Oxo
Chemie, which is currently being tested for the treatment of
HIV/AIDS and cancer. Marketing approval for PENNSAID(tm) has
been sought in both Canada and the United Kingdom with an
application expected to be made in the United States later
this year.
FOR FURTHER INFORMATION PLEASE CONTACT:
Dimethaid Research Inc.
Peter Block
Investor Relations Manager
(905) 415-1446
www.dimethaid.com
e-mail: pblockdimethaid.co |
|
